Octin Health raises $2.5M to rethink aortic arch surgery
What's the deal? Octin HealthDealroom has a profile for this one. Try Dealroom →, a Minneapolis medical device startup, raised $2.5 million in seed funding from Groove CapitalDealroom has a profile for this one. Try Dealroom → and the Minnesota Women's Investment Collective. The money will help bring its device, Elika, to market.
What's the endgame? Aortic arch surgery currently relies on deep hypothermic circulatory arrest — cooling patients to between 18 and 20 degrees Celsius, stopping the heart, and working against a 40-minute clock before brain damage sets in. Elika is designed to keep blood flowing to the brain and vital organs while surgeons occlude the aorta, eliminating that workaround.
Why now? Founder Meghana Helder, a cardiovascular surgeon trained at Mayo ClinicDealroom has a profile for this one. Try Dealroom →, started the company in 2024 after watching patients survive surgery only to wake with strokes and organ failure. The startup plans an FDA submission in 2027.
The stakes are high. Aortic arch operations carry operative mortality rates of roughly 16% to 20%, and complications from the current technique strike up to 39% of patients, according to a review in the Journal of Cardiothoracic and Vascular Anesthesia . Disabling strokes occur in about 6% of cases.
What could go wrong? The medical device market is expensive and unforgiving, and the path from prototype to FDA clearance is long. To improve its odds, Octin assembled a team of veterans from Boston Scientific, PhilipsDealroom has a profile for this one. Try Dealroom →, and CovidienDealroom has a profile for this one. Try Dealroom →, alongside a board that includes Scott Ward, former chief executive officer of Cardiovascular SystemsDealroom has a profile for this one. Try Dealroom →, which Abbott bought for $851 million in 2023.
The signal: At $2.5 million, this is a modest seed round for a hardware-heavy medtech company facing years of validation. But a surgeon-founded startup tackling a decades-old surgical compromise — backed by operators and clinicians who have navigated the regulatory gauntlet before — signals investor appetite for devices that target the highest-risk, highest-mortality procedures.
Image credit: Octin Health, Inc
